Research programme: high mobility group box chromosomal protein-1 inhibitors - Nautilus/Sienna BiopharmaceuticalsAlternative Names: CT500 variant - Nautilus/Sienna Biopharmaceuticals; HMGB-1 inhibitors - Nautilus/Sienna Biopharmaceuticals; Improved CT500
Latest Information Update: 15 Dec 2016
At a glance
- Originator Creabilis Therapeutics; Nautilus Biotech
- Class Proteins
- Mechanism of Action Cytokine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis; Sepsis